Navigation Links
Driven by the Uptake of Several Emerging Agents, the MRSA Drug Market Will Increase From $631 Million in 2009 to $752 Million in 2019
Date:11/10/2010

BURLINGTON, Mass., Nov. 10, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the methicillin-resistant Staphylococcus aureus (MRSA) drug market will increase from $631 million in 2009 to $752 million in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Methicillin-resistant Staphylococcus aureus (MRSA) finds that market growth will be driven by the uptake of several emerging agents that include Forest/AstraZeneca/Takeda's ceftaroline (Teflaro) and Trius Therapeutics' torezolid, a second-generation oxazolidinone. Ceftaroline recently received FDA approval for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia, while torezolid began its first Phase III trial in ABSSSIs in August 2010. Together, these two agents will capture more than one-third of the overall MRSA market in 2019.

"The late-stage MRSA pipeline is diverse, spanning several antibiotic classes, including many first-in-class broad-spectrum anti-MRSA agents from well-established classes: cephalosporins, quinolones and fusidanes," said Decision Resources Analyst Charu Vepari, Ph.D. "In contrast to the current MRSA armamentarium consisting largely of narrow-spectrum agents, most of the new MRSA therapies entering the market in the next decade will be broad-spectrum agents."

The MRSA pipeline is also comprised of several new therapies being developed in both intravenous (IV) and oral formulations, indicating that developers have recognized the need and opportunity for oral MRSA therapies for both the hospital and community setting. Agents with dual IV and oral formulations include torezolid, Rib-X's delafloxacin and Novartis/Paratek's amadacycline. In the coming decade, numerous emerging products are poised to address the need for interchangeable IV and oral formulations.

The Pharmacor 2010 findings also reveal that the recent approval and pending launch of the broad-spectrum, first-in-class anti-MRSA cephalosporin—ceftaroline (estimated launch in January, 2011)—will change class dynamics and bring cephalosporins to the forefront of the MRSA armamentarium. Because of its broad and expanded activity against MRSA, ceftaroline is well-positioned for use as a first-line empiric therapy for suspected MRSA infections. Basilea's ceftobiprole, ceftaroline's once formidable competitor, was denied FDA approval for complicated skin and skin structure infections in December 2009 and was unable to receive European marketing authorization in February 2010. Consequently, ceftaroline will be the first and only MRSA cephalosporin on the market for the foreseeable future, given uncertainty about continued development of ceftobiprole."We believe ceftaroline will enjoy significant commercial success, earning $150 to 200 million in peak year major-market sales for MRSA infections," Dr. Vepari said.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TeleHealth Services and Reading Hospital and Medical Center Partner to Reach Technology-Driven Patient Education Goals
2. Driven by Sales of Lyrica, Cymbalta/Xeristar and Savella, the Fibromyalgia Drug Market Will Experience 4.2 Percent Annual Growth Through 2018
3. Increasing Potential for RIS-driven PACS Modules in Europe, Finds Frost & Sullivan
4. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
5. GeneGo Releases Content and Tools From Industry-FDA Driven MetaTox Partnership Via ToxHunter(TM)
6. Energetiq Introduces Laser-Driven Light Sources for Biophysical Applications
7. The Cancer Pain Drug Market, Driven by the Continued Dominance of Opioids, Will Increase From $2.3 Billion in 2008 to $3.7 Billion in 2018
8. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015
11. The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017 ... has recognized the company with their  2017 New Product Innovation ... is based on extensive primary and secondary medical device market ... AVACEN Medical, through its first-to-market OTC, drug-free pain relief product, ... a unique approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
Breaking Medicine News(10 mins):